ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 29, 2018--
Therapeutics, Inc. (NYSE American: AGE), a biotechnology company
focused on the development and commercialization of therapeutics
targeting human aging, announced that its Founder and CEO Michael D.
West, Ph.D. will present a keynote address at the Advanced
Stem Cell & Regenerative Medicine conference 2018 in Valencia,
Spain on Monday December 3, 2018.
In his address, Dr. West will provide an update on AgeX product
development, and will for the first time present data on the potential
use of its proprietary induced Tissue Regeneration (iTRTM)
technology in cancer diagnosis and therapy as well as in inducing the
destruction of aged cells (a process known as “senolysis”).
A copy of Dr. West’s presentation will be available on AgeX’s website at www.agexinc.com.
About Induced Tissue Regeneration (iTRTM)
The premise behind iTR is that aging, and in turn, diseases of old age,
are due to two characteristics that are present in the cells in our body
when it is first forming but that are lost with time. These
Replicative immortality of cells
Regenerative capacity of cells
Leveraging our assets in pluripotency and bioinformatics, AgeX
scientists have performed research in cellular immortality and
regenerative biology, comparing cells in the first stages of life with
those in old age. In 2010, while at BioTime, AgeX scientists
demonstrated the reversal
of the developmental aging of human cells using transcriptional
reprogramming technology. In 2017, they published
certain genes that were turned off or turned on at the same time
regenerative potential was lost.
The AgeX scientific team subsequently extended this research to
determine whether reprogramming can be modified to only reverse the
aging of cells back to a regenerative state, not back to pluripotency.
For example, the team has utilized the gene COX7A1 as a
marker of cells that have lost regenerative potential. AgeX’s
proprietary formulation AGEX-iTR1547 has demonstrated initial capability
of reducing the expression of the marker gene COX7A1 and
is currently performing research to optimize a potential pharmaceutical
preparation to reverse the aging of human tissues and thereby restore
When implemented in vivo, this partial reprogramming, or
iTR, would be expected to induce tissue regeneration, and when combined
with telomerase, could modulate both cellular immortality and
regenerative biology for therapeutic effect.
In addition, RenelonTM, a first-generation
product candidate under development at AgeX, utilizes a repurposed drug
formatted in the company’s HyStem® hydrogels,
and is planned for initial development as a device for topical
application. While not capable of fully transporting cells back to a
regenerative state, the anticipated ability of Renelon to
impart scarless tissue repair could provide significant benefits to
AgeX is a biotechnology company focused on the development of novel
therapeutics for age-related degenerative disease. AgeX’s mission is to
apply the proprietary technology platform related to telomerase-mediated
cell immortality and regenerative biology to address a broad range of
diseases of aging. The current preclinical development efforts include
two cell-based therapies derived from telomerase-positive pluripotent
stem cells and two product candidates derived from the company’s
proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and
AGEX-VASC1 are cell-based approaches in the preclinical stage of
development comprised of young regenerative cells modified using AgeX’s
UniverCyte™ technology facilitating immune tolerance, formulated in
HyStem® matrix, designed to correct metabolic imbalances in
aging and to restore vascular support in ischemic tissues respectively.
AGEX-iTR1547 is a drug-based formulation in preclinical development
intended to restore regenerative potential in a wide array of aged
tissues afflicted with degenerative disease using the company’s
proprietary iTR technology. Renelon™ is a first-generation iTR product
designed to promote scarless tissue repair which AgeX plans to initially
develop as a topically-administered device for commercial development
through a 510(k) application. In addition to the product candidates in
early development, AgeX, through its LifeMap subsidiary, currently
markets genomic interpretation algorithms. AgeX also markets Cytiva®
comprised of PSC-derived heart muscle cells used in screening drugs for
efficacy and safety.
For more information, please visit www.agexinc.com
or connect with the company on Twitter,
Certain statements contained in
this release are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements that
are not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and uncertainties.
Actual results may differ materially from the results anticipated in
these forward-looking statements and as such should be evaluated
together with the many uncertainties that affect the business of AgeX
Therapeutics, Inc. and its subsidiaries, particularly those mentioned in
the cautionary statements found in more detail in the “Risk Factors”
section of AgeX’s Information Statement filed as an exhibit to its
Registration Statement on Form 10 with the Securities and Exchange
Commissions (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181129005306/en/
Source: AgeX Therapeutics, Inc.
Gotham Communications, LLC
Next Level Agency, Inc.